PT - JOURNAL ARTICLE AU - Genay Pilarowski AU - Paul Lebel AU - Sara Sunshine AU - Jamin Liu AU - Emily Crawford AU - Carina Marquez AU - Luis Rubio AU - Gabriel Chamie AU - Jackie Martinez AU - James Peng AU - Douglas Black AU - Wesley Wu AU - John Pak AU - Matthew T. Laurie AU - Diane Jones AU - Steve Miller AU - Jon Jacobo AU - Susana Rojas AU - Susy Rojas AU - Robert Nakamura AU - Valerie Tulier-Laiwa AU - Maya Petersen AU - Diane V. Havlir AU - The CLIAHUB Consortium AU - Joseph DeRisi TI - Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco AID - 10.1101/2020.11.02.20223891 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.02.20223891 4099 - http://medrxiv.org/content/early/2020/11/12/2020.11.02.20223891.short 4100 - http://medrxiv.org/content/early/2020/11/12/2020.11.02.20223891.full AB - We evaluated the performance of the Abbott BinaxNOW™ Covid-19 rapid antigen test to detect virus among persons, regardless of symptoms, at a public plaza site of ongoing community transmission. Titration with cultured clinical SARS-CoV-2 yielded a human observable threshold between 1.6×104-4.3×104 viral RNA copies (cycle threshold (Ct) of 30.3-28.8 in this assay). Among 878 subjects tested, 3% (26/878) were positive by RT-PCR, of which 15/26 had a Ct<30, indicating high viral load. 40% (6/15) of Ct<30 were asymptomatic. Using this Ct<30 threshold for Binax-CoV2 evaluation, the sensitivity of the Binax-CoV2 was 93.3% (14/15), 95% CI: 68.1-99.8%, and the specificity was 99.9% (855/856), 95% CI: 99.4-99.9%.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by UCSF, the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative, the San Francisco Latino Task Force, and a private donor. LR was funded by T32 AI060530, and SS was funded by F31AI150007.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSF Committee on Human Research determined that the study met criteria for public health surveillance. All participants provided informed consent for dual testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is included in the figures of the manuscript. Supplemental material (Binax-CoV2 reader training guide) is included in the link. https://unitedinhealth.org/binax-training